Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer

PURPOSE: Early studies of patients with castration-resistant metastatic prostate cancer (CRMPC) suggest that chemotherapy administered with a dose of a bone-seeking radiopharmaceutical is superior to chemotherapy alone. To build on this strategy and fully integrate a repetitively dosed bone-seeking...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Morris, Michael J., Pandit-Taskar, Neeta, Carrasquillo, Jorge, Divgi, Chaitanya R., Slovin, Susan, Kelly, William K., Rathkopf, Dana, Gignac, Gretchen A., Solit, David, Schwartz, Lawrence, Stephenson, Ryan D., Hong, Christina, Delacruz, Anthony, Curley, Tracy, Heller, Glenn, Jia, Xiaoyu, O'Donoghue, Joseph, Larson, Steven, Scher, Howard I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2009
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2684850/
https://ncbi.nlm.nih.gov/pubmed/19364960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.4164
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller